Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Doccoleon May 08, 2021 8:24am
173 Views
Post# 33159302

RE:Current status

RE:Current statusAgreed, here in the US our hospitals are opening up and business as usual is occurring/starting.  Covid changed the delivery methods we practice medicine, but I would say from a personal standpoint, barriers here should be reduced by end of summer.  

Name of the game - supply and demand.  We will have a increase insider stock ownership- that will support the price.  Once this hits the Nasdq we will need big blocks bought from major institutional investors to grow it.

here is my number and prediction-
we will move up over June and July to around 9 US with a MC of 600m.  We will have a Nasdq push August/September.  That will take ATE to 1b MC 15US fall.

now I believe there will be regional deals/news along the way that will Alter this, but this is my logic.  A buyout to me would be North of 3b if not more.  The MC and stock price is not reflective of the science, IP and potential.

for our baseball fans, we have a prospect ready to jump to the majors.  Waiting on the September call up!

good luck Canadian friends!
<< Previous
Bullboard Posts
Next >>